Alpha 2.0
Login Register
» Articles » PMID: 2582776

Single-dose Kinetics of Recombinant Human Erythropoietin After Intravenous, Subcutaneous and Intraperitoneal Administration. Preliminary Results

Overview
Journal Contrib Nephrol
Specialty Nephrology
Date 1989 Jan 1
PMID 2582776
Citations 10
Authors
D Kampf
A Kahl
J Passlick
A Pustelnik
K U Eckardt
B Ehmer
C Jacobs
A Baumelou
B Grabensee
G M Gahl
Affiliations
Soon will be listed here.
Citing Articles

Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Doshi S, Krzyzanski W, Yue S, Elliott S, Chow A, Perez-Ruixo J Clin Pharmacokinet. 2013; 52(12):1063-83.

PMID: 23912564 DOI: 10.1007/s40262-013-0098-x.

Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Neelakantan S, Widness J, Schmidt R, Veng-Pedersen P Pediatr Int. 2009; 51(1):25-32.

PMID: 19371274 PMC: 2871397. DOI: 10.1111/j.1442-200X.2008.02648.x.

The absorption of darbepoetin alfa occurs predominantly via the lymphatics following subcutaneous administration to sheep.

McLennan D, Porter C, Edwards G, Heatherington A, Martin S, Charman S Pharm Res. 2006; 23(9):2060-6.

PMID: 16951999 DOI: 10.1007/s11095-006-9064-8.

Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Perez-Oliva J, Casanova-Gonzalez M, Garcia-Garcia I, Porrero-Martin P, Valenzuela-Silva C, Hernandez-Montero T BMC Nephrol. 2005; 6:5.

PMID: 15910687 PMC: 1164417. DOI: 10.1186/1471-2369-6-5.

Subcutaneous r-HuEPO therapy in CAPD patients: dose determination and clinical experience.

JANICKA L, Ksiazek A, Baranowicz I, Bednarek-Skublewska A, Mierzicki P, Ksiazek P Int Urol Nephrol. 1998; 30(1):91-7.

PMID: 9569119 DOI: 10.1007/BF02550285.